- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Direct-Acting Oral Anticoagulants: Treatment Considerations
For patients at risk for thromboembolic complications who have trouble with adherence to warfarin therapy or prefer not to be treated with warfarin, newer direct-acting oral anticoagulants may be an option. Michael A. Evans, BS, RPh, explores the advantages and limitations of treating patients with direct-acting oral anticoagulants.
Mr Evans remarks that unlike with warfarin, regular monitoring is not required with the direct-acting oral anticoagulants, as their anticoagulant effect is predictable. There are no known food interactions with the direct-acting oral anticoagulants; however, drug-drug interactions are still of concern.
The direct-acting oral anticoagulants have a short half-life, and thus missed doses and a lack of patient adherence leave patients at risk for thromboembolic events within a short time frame, says Mr Evans.
Should a patient who is being treated with a direct-acting oral anticoagulant experience a thromboembolic event, it is more difficult to determine whether the event was related to a lack of adherence or drug failure, notes Mr Evans. This may be easier to determine for patients who are treated with warfarin, he adds.
Mr Evans explains that a patient’s age, their risk for bleeding events, and cost are all factors that affect a physician’s decision to treat a patient with warfarin versus a direct-acting oral anticoagulant.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Study Highlights Disparities in Access to In-Network Mental Health Care vs Medical Care
April 17th 2024While health plans often employ reimbursement rates as a tool to incentivize provider participation within their networks, study results showed reimbursement rates for office visits with medical/surgical clinicians were on average 22% higher than behavioral health clinicians.
Read More
